Sunday, April 26, 2015

Cannabis Science

COLORADO SPRINGS, Colo., April 22, 2015 -- Cannabis Science, Inc. (OTCQB: CBIS), a U.S. company specializing in the development of cannabis-based medicine and related consulting, is pleased to announce the acceptance of its presentation next month at the 28th International Conference on Antiviral Research (ICAR) in Rome, Italy.
"We are happy to see this important conference supporting and enabling exposure to the scientific community of the prospective health benefits that cannabinoids have in diseases such as HIV and AIDS," stated Roscoe M. Moore, Jr., D.V.M., Ph.D., D.Sc., Assistant U.S. Surgeon General (Retired), Special Senior Advisor to Cannabis Science, Inc.
"The Company's presentation at ICAR in Rome provides more validation of our scientific approach to cannabinoid-based drug development, particularly in the context of the HIV pandemic, and highlights the acumen of our first class team of experts," said Raymond C. Dabney, Co-Founder, President and CEO of Cannabis Science, Inc.
The peer-reviewed presentation accepted by the ICAR conference committee is a review of peer-reviewed literature finding numerous benefits of cannabinoids in Kaposi sarcoma and HIV. The "poster" concludes that "[f]urther research on the clinical utility and consequences of cannabinoids is necessary to identify new opportunities for cannabinoid-based drug development for HIV patients to target insults to endothelial and microglial cells. Further research on cannabinoids is anticipated in addressing HIV-associated neurocognitive disorder, suppressing inflammatory cytokines and latent pools of resting viremia in macrophages and other cell lines that are currently representing global challenges to HIV eradication."
The International Conference on Antiviral Research, which takes place on May 11 to May 15, 2015 at the Parco dei Principi Hotel in Rome, Italy, is an annual gathering of biologists, chemists and clinicians interested in antiviral therapeutic and prevention agent research and development. ICAR is sponsored by the International Society of Antiviral Research. Topics discussed at the conference include: medicinal chemistry, virus replication, host cell-virus interactions, virus latency, new target identification, biochemistry and mechanism of action, mechanisms of viral drug resistance, assay development, in vitro evaluation, animal models, pharmacokinetics, toxicology, and clinical trials.
About Cannabis Science, Inc. Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions.  The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus:  CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
Forward-Looking Statements This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward-looking statements.  Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties.  These forward-looking statements may be impacted, either positively or negatively, by various factors.  Information concerning potential factors that could affect the company are detailed from time to time in the company's reports filed with the Securities and Exchange Commission.
Cannabis Science, Inc. Mr. Derwin A. Wallace
Finance & Investor Relations 
Tel: 1.888.889.0888 FREE
Direct: 1.404.500.4950
Mr. Raymond C. Dabney
President & CEO, Co-Founder 
Tel: 1.888.889.0888 FREE

SOURCE Cannabis Science, Inc

Saturday, April 25, 2015

Rise in cost of MS drugs over past two decades

Study shows cost of multiple sclerosis drugs increased five to seven times greater than prescription drug inflation; researchers voice concern about patient access to life-changing treatments


PORTLAND, Ore., April 24, 2015 / -- A new study shows an "alarming rise" over the last 20 years in the costs of drugs used to slow the progression of multiple sclerosis or reduce the frequency of attacks, according to a study led by researchers at Oregon Health & Science University (OHSU) and Oregon State University (OSU).
A substantial increase in the number of MS drugs in the marketplace over the past 20 years, paradoxically, did not lead to lower or stabilized costs for patients who use those drugs. Researchers found the costs of all drugs used to treat MS – including first-generation therapies – skyrocketed. Their work is published online today in the May 26, 2015, issue of Neurology®, the medical journal of the American Academy of Neurology.
The costs of MS drugs accelerated at rates five to seven times higher than prescription drug inflation and substantially higher than rates for drugs in a similar class between 1993 and 2013, the researchers report. Drug costs for several MS agents rose on average 20 to 30 percent per year over this time period.
In response to mounting concerns about the affordability of drugs used to treat MS, researchers examined 20 years of drug pricing data for nine MS drug treatments beginning with the initially approved injectable medications, up through the approval of the newest oral drugs.
"The inexplicable increase in the cost of MS drugs, particularly older, first- generation drugs, is at odds with how we think the marketplace should work. A growth in the number of MS drugs should lower costs for patients. What we see here is the opposite happened: costs have risen sharply, and at a pace that's far greater than drugs in a similar biologic class," said Daniel M. Hartung, Pharm.D., M.P.H., lead author of the study and associate professor in the OSU/OHSU College of Pharmacy.
Researchers found that long-standing drugs, such as Betaseron™, Avonex™ and Copaxone™, originally costing $8,000 to $11,000, now cost approximately $60,000 per year  – an average increase of 21 to 36 percent annually. Their cost acceleration corresponded with the approval of newer agents, including Gilenya™, Aubagio™, and Tecfidera™, which have increased 8 to 17 percent annually since their approval. During that same period, general and prescription drug inflation only increased 3 to 5 percent per year.
The study shows that U.S. prices for MS drugs were also out of step with costs in other developed countries. In comparing current U.S. costs for all MS drugs with estimates from the United Kingdom, Canada and Australia, researchers found that the costs of MS drugs in the U.S. market are two to three times higher. MS drug costs in those industrialized countries were often more than 70 percent lower than U.S. costs.
Researchers also examined the costs paid by the U.S. Department of Veterans Affairs (VA) because of its ability to negotiate discounts directly with manufacturers. Their analysis shows that on average costs for the VA were 36 percent less than those paid by Medicaid, including a nearly 80 percent discount for Betaseron™. This cost disparity suggests the sharp rise in U.S. prices is not the result of increases in manufacturing costs.
"This study confirms what many of us treating patients with MS had suspected: The pricing trajectories of MS drugs are unsustainable for our health care system and need to be addressed," said Dennis N. Bourdette, M.D., F.A.N.A., F.A.A.N., co-author of the study and chair of the Department of Neurology in the OHSU School of Medicine and executive director of the Multiple Sclerosis Center at OHSU.
The lack of transparency within pharmaceutical pricing and purchasing, and the absence of a national health care system within the U.S. to negotiate prices directly with the pharmaceutical industry may have contributed to the soaring costs of these drugs, according to the researchers.
"As a doctor, I'm deeply concerned about making sure these life-changing drugs are within reach for patients. The driving force behind this study was our experience that the high cost of MS drugs interferes with our ability to take good care of our patients," said Ruth H. Whitham, M.D., F.A.A.N., co-author of the study, professor of neurology in the OHSU School of Medicine, and co-founder of the Multiple Sclerosis Center at OHSU.
"We decided to shine a light on this growing problem so that those of us who care for patients with chronic illness can work together and advocate for changes to drug pricing mechanisms."
"The Cost of Multiple Sclerosis Drugs in the U.S. and the Pharmaceutical Industry: Too big to fail?" was authored by Daniel M. Hartung, Pharm.D., M.P.H.; Dennis N. Bourdette, M.D., F.A.N.A., F.A.A.N.; Sharia Ahmed, M.P.H.; Ruth H. Whitham, M.D., F.A.A.N.
About OHSU
Oregon Health & Science University is a nationally prominent research university and Oregon's only public academic health center. It serves patients throughout the region with a Level 1 trauma center and nationally recognized Doernbecher Children's Hospital. OHSU operates dental, medical, nursing and pharmacy schools that rank high both in research funding and in meeting the university's social mission. OHSU's Knight Cancer Institute helped pioneer personalized medicine through a discovery that identified how to shut down cells that enable cancer to grow without harming healthy ones. OHSU Brain Institute scientists are nationally recognized for discoveries that have led to a better understanding of Alzheimer's disease and new treatments for Parkinson's disease, multiple sclerosis and stroke. OHSU's Casey Eye Institute is a global leader in ophthalmic imaging, and in clinical trials related to eye disease.
About the OSU/OHSU College of Pharmacy
The College of Pharmacy prepares students to be pharmacy practitioners and pharmaceutical sciences researchers able to advance societal health through leadership in pharmacy education, research, community engagement, and improved patient care.
Media Toolkit
Download photos of the study's authors on OHSU News.
Related Content
The study can be found on the website of the journal Neurology®.

SOURCE Oregon Health & Science University


Tuesday, April 21, 2015

The Science of Happiness

Woman, Happiness, Sunrise, Silhouette
If it were possible to live without dreams we would have avoided many problems.

But life is a dream, it is not possible to live without dreams and I not talk about the night dream, but what we live every day.
Imagine for a moment, a television advertising , a deodorant, a simple chemical deodorant, anything special as all deodorants, a normal price like all the air fresheners - why should we choose to buy that deodorant? If the television inform me about there deodorant that is composed of chemical elements like any other air fresheners, is not interesting for me, I do not want this information, because this does not help me to live, I want's dreams, because  the reality is sad, the reality is harsh and sometimes frightening.
I mean, the reality is different for each of us but at the same time it homogenized by the stereotypes imposed from the society. The society, which becomes a subject detached from us, despite being borne by us. So, what corresponds to the happiness? What are the real parameter able to establish their value?  

Consider the example of someone who is with no money for a period longer or shorter, or those who are hungry or thirsty. In each of these cases, the level of happiness decreases inexorably. Conversely, for a person living in the material or spiritual well-being, the level of happiness rises. As if the bar would shift increasingly to make impregnable a state of consciousness that must remain limited in time, in the moments and absolutely can not be a permanent condition.
Then occurs that the concept of happiness is changed permanently, so as to make it impossible to achieve the goal if not for a few moments in which the rich man enjoys a new game, it quenches thirsty and hungry feeds. Here is that our mind invents the dream, a life unreal. We go to the cinema to live a life that does not exist, unreal characters, music stimulates our emotional, and tell us about the false advertising. Take the procreative act in a fictional context, away from the primordial instinct. We make war, we object to the war. We would like to live in a tropical island while their population make improbable trips for to live in our crowded and chaotic city.

The happiness is a chemical formulaMaybe!  
Women in the Andes chewed coca leaves to endure the hardships of the day while in Paris Marie Antoinette introduced his underwear. Everything is relative and everything expands before being allowed another dream, behind the real, as difficult to find, concealed from the dreams that  inexorable  we hasten to build, as mantles of sand to hide the night.